Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06246968 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

StatusRecruiting
PhasePhase 1
Started2024-01-29
View on ClinicalTrials.gov ↗
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with ablation (cryoablation or histotripsy) OR pembrolizumab alone. Participants will be randomly assigned.

Amendment history 2 changes detected by DataLookout

2026-09-15
Primary endpoint(s) modified
WasChange in CD4-PD1 from baseline to post-cryoablation
NowChange in CD4-PD1 from baseline to post-ablation
2026-09-15
Interventions modified
Trial Details
NCT Number NCT06246968
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Metastatic Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma
Enrollment 30 participants
Start Date 2024-01-29
Primary Completion 2027-01-29 (estimated)
Study Completion 2027-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-09-14